Rapid Rx Quiz: Semaglutide

Mary L. Windle, PharmD


January 20, 2022

In clinical trials, cholelithiasis was reported by 1.6% of those taking semaglutide and 0.7% of those taking placebo. In terms of cholecystitis, the rates were 0.6% with the higher dose of semaglutide vs 0.2% with placebo. Impotence, mucositis, and hyperhidrosis have not been cited as significant concerns associated with semaglutide use.

Learn more about adverse effects associated with semaglutide.

This Fast Five Quiz was excerpted and adapted from the Medscape articles semaglutide, More STEP Data: Semaglutide Cuts Weight, Cravings, Beats Liraglutide, All About Wegovy for Weight Loss, and Type 2 Diabetes Mellitus Treatment & Management.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.